Cargando…

SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors

Undoubtedly, the development of COVID-19 vaccines displays a critical step towards ending this devastating pandemic, considering their protective benefits in the general population. Yet, data regarding their efficacy and safety in cancer patients are limited. Herein we provide the initial analysis o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zagouri, Flora, Terpos, Evangelos, Fiste, Oraianthi, Liontos, Michalis, Briasoulis, Alexandros, Katsiana, Ioanna, Skafida, Efi, Markellos, Christos, Kunadis, Elena, Andrikopoulou, Angeliki, Kaparelou, Maria, Koutsoukos, Konstantinos, Gavriatopoulou, Maria, Kastritis, Efstathios, Trougakos, Ioannis P., Dimopoulos, Meletios-Athanasios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402928/ https://www.ncbi.nlm.nih.gov/pubmed/34481366 http://dx.doi.org/10.1016/j.breast.2021.08.017

Ejemplares similares

Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
por: Liontos, Michalis, et al.
Publicado: (2021)

Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients
por: Liontos, Michalis, et al.
Publicado: (2021)

CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents
por: Zagouri, Flora, et al.
Publicado: (2022)

SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition
por: Terpos, Evangelos, et al.
Publicado: (2022)

Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience
por: Liontos, Michalis, et al.
Publicado: (2021)

BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients
por: Liontos, Michalis, et al.
Publicado: (2021)

The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma
por: Fiste, Oraianthi, et al.
Publicado: (2021)

What to expect from paraneoplastic syndromes of the nervous system in uterine cancer: A review of the literature
por: Svarna, Anna, et al.
Publicado: (2023)

Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review
por: Fiste, Oraianthi, et al.
Publicado: (2020)

Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses
por: Georgakopoulou, Rebecca, et al.
Publicado: (2021)

Subarachnoid hemorrhage in a postpartum mother: A rare manifestation of an uncommon disease
por: Fiste, Oraianthi, et al.
Publicado: (2022)

Advances in Gynecological Cancers
por: Liontos, Michalis, et al.
Publicado: (2022)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
por: Skafida, Efthymia, et al.
Publicado: (2023)

Pembrolizumab in endometrial cancer: Where we stand now
por: Aravantinou-Fatorou, Aikaterini, et al.
Publicado: (2021)

Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit
por: Liontos, Michalis, et al.
Publicado: (2021)

MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
por: Terpos, Evangelos, et al.
Publicado: (2021)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
por: Liontos, M., et al.
Publicado: (2021)

“The emerging role of capivasertib in breast cancer”
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer
por: Zografos, Eleni, et al.
Publicado: (2022)

Paraneoplastic cerebellar degeneration in platinum-responsive endometrial cancer: A case report and review of literature
por: Liontos, Michalis, et al.
Publicado: (2021)

Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19
por: Liontos, Michalis, et al.
Publicado: (2020)

Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
por: Kaparelou, Maria, et al.
Publicado: (2022)

77P The impact of COVID-19 on gynecological cancer diagnoses in Greece
por: Fiste, O., et al.
Publicado: (2023)

Secondary Alopecia Neoplastica Mimicking Alopecia Areata following Breast Cancer
por: Skafida, Efthymia, et al.
Publicado: (2020)

TP53 mutations determined by targeted NGS in breast cancer: a case-control study
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Clinical Perspectives of ERCC1 in Bladder Cancer
por: Koutsoukos, Konstantinos, et al.
Publicado: (2020)

Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting
por: Liontos, Michalis, et al.
Publicado: (2021)

Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2020)

The emerging role of BET inhibitors in breast cancer
por: Andrikopoulou, A., et al.
Publicado: (2020)

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature
por: Papatheodoridi, Alkistis, et al.
Publicado: (2023)

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
por: Terpos, Evangelos, et al.
Publicado: (2022)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Axitinib as a third or further line of treatment in renal cancer: a single institution experience
por: Tsironis, G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5msq332cpjdnfp83c9ahbtgeb8